OverviewSuggest Edit

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The Company's pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
TypePublic
Founded1983
HQHampton, US
Websitecelldex.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2018)133(-30%)
Job Openings3
Revenue (FY, 2018)$9.5 M(-25%)
Share Price (Oct 2019)$2.4

Key People/Management at Celldex Therapeutics

Anthony Marucci

Anthony Marucci

Founder, President & CEO
Tibor Keler

Tibor Keler

Founder, SVP & CSO
Thomas Davis

Thomas Davis

Svp & CMO
Ronald A. Pepin

Ronald A. Pepin

SVP & Chief Business Officer
Show more

Celldex Therapeutics Office Locations

Celldex Therapeutics has offices in Hampton, Branford, Fall River and Needham
Hampton, US (HQ)
53 I-78 Frontage Rd #220
Branford, US
688 E Main St #1a
Fall River, US
UMass Dartmouth Center for Innovation & Entrepreneurship, 151 Martine St
Needham, US
119 4th Ave, Needham Heights
Show all (4)

Celldex Therapeutics Financials and Metrics

Celldex Therapeutics Revenue

Celldex Therapeutics's revenue was reported to be $9.54 m in FY, 2018
USD

Revenue (Q2, 2019)

715.0k

Net income (Q2, 2019)

(11.8m)

EBIT (Q2, 2019)

(12.3m)

Market capitalization (16-Oct-2019)

36.0m

Closing stock price (16-Oct-2019)

2.4

Cash (30-Jun-2019)

19.7m

EV

18.8m
Celldex Therapeutics's current market capitalization is $36 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2016FY, 2017FY, 2018

Revenue

4.1m3.6m5.5m6.8m12.7m9.5m

Revenue growth, %

(13%)53%24%

General and administrative expense

14.8m33.8m36.0m25.0m19.3m

R&D expense

67.4m100.2m102.7m96.2m66.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019

Revenue

980.0k416.0k592.0k1.1m2.2m1.0m1.3m1.4m2.2m1.5m3.8m3.9m4.1m2.8m1.4m715.0k

General and administrative expense

3.6m4.6m4.8m5.0m8.2m8.5m9.3m7.8m7.0m7.2m6.5m5.3m5.6m5.6m4.9m3.9m

R&D expense

20.4m27.1m24.1m26.2m26.5m24.7m27.4m25.7m25.0m25.8m25.0m21.9m21.9m21.4m11.2m10.1m

Operating expense total

24.2m31.9m29.1m31.4m34.9m33.4m37.0m33.8m32.2m36.6m32.8m35.9m123.7m19.6m19.4m13.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

169.4m28.0m72.1m42.5m40.3m24.3m

Accounts Receivable

489.0k427.0k97.0k1.8m

Current Assets

305.2m205.0m294.9m195.6m144.8m99.1m

PP&E

10.0m10.5m11.5m13.2m10.4m6.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(81.5m)(118.1m)(127.2m)(128.5m)(93.0m)(151.2m)

Depreciation and Amortization

1.9m2.4m3.0m3.1m4.4m3.6m

Accounts Payable

7.2m1.5m4.9m(5.0m)(8.7m)(13.1m)

Cash From Operating Activities

(67.7m)(101.5m)(98.9m)(113.0m)(99.9m)(75.2m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019

Net Income

(59.5m)(29.9m)(58.2m)(86.3m)(32.4m)(32.0m)(34.7m)(32.0m)(29.6m)(34.3m)(62.8m)(89.2m)(118.1m)(134.5m)(17.2m)(29.0m)

Depreciation and Amortization

1.4m579.0k1.2m1.8m1.4m2.4m3.4m1.0m2.0m1.4m2.5m

Accounts Payable

3.0m(1.7m)(1.0m)(740.0k)3.1m2.0m1.2m2.6m706.0k1.0m(8.3m)(6.8m)(10.9m)(5.9m)(5.9m)(1.5m)(1.6m)

Cash From Operating Activities

(52.7m)(31.9m)(52.7m)(79.3m)(35.3m)(56.0m)(80.4m)(28.0m)(45.4m)(13.2m)(24.3m)
USDY, 2019

EV/EBIT

-1.5 x

EV/CFO

-0.8 x

Financial Leverage

1.3 x
Show all financial metrics

Celldex Therapeutics Operating Metrics

FY, 2016

Patents Issued

300
Show all operating metrics

Celldex Therapeutics Online and Social Media Presence

Embed Graph

Celldex Therapeutics News and Updates

Celldex Therapeutics Announces Reverse Stock Split

HAMPTON, N.J., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary o…

Celldex Therapeutics Blogs

Celldex Provides Corporate Update and Reports Second Quarter 2019 Results

Celldex Provides Corporate Update and Reports Second Quarter 2019 Results Content Import Wed, 08/07/2019 - 16:02 Celldex Provides Corporate Update and Reports Second Quarter 2019 Results Aug 7, 2019 This release is a backfill from a News Wire Ea…

Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call

Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call Content Import Wed, 07/31/2019 - 16:01 Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call Jul 31, 2019 This release is a backfill from a …

Karen L. Shoos, J.D.

Karen L. Shoos, J.D. jennifer.segal… Fri, 06/28/2019 - 09:41 Member of the Nominating and Corporate Governance Committee Karen L. Shoos, J.D. Chair; Consultant, AABB International Technical Assistance, Division of Global Services Ms. Shoos was appointed Chair of the …

Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer

HAMPTON, N.J. , June 24, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the appointment of Diane C. Young , M.D., as Senior Vice President, Chief Medical Officer, effective July 8, 2019 . Over the span of a 30 year career, Dr.

Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019

Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019 jennifer.segal… Tue, 04/02/2019 - 08:13 Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at Amer…

Celldex Provides Corporate Update and Reports Full Year 2018 Results

Celldex Provides Corporate Update and Reports Full Year 2018 Results Content Import Thu, 03/07/2019 - 16:05 Celldex Provides Corporate Update and Reports Full Year 2018 Results Mar 7, 2019 This release is a backfill from a News Wire Earnings …
Show more

Celldex Therapeutics Frequently Asked Questions

  • When was Celldex Therapeutics founded?

    Celldex Therapeutics was founded in 1983.

  • Who are Celldex Therapeutics key executives?

    Celldex Therapeutics's key executives are Anthony Marucci, Tibor Keler and Thomas Davis.

  • How many employees does Celldex Therapeutics have?

    Celldex Therapeutics has 133 employees.

  • What is Celldex Therapeutics revenue?

    Latest Celldex Therapeutics annual revenue is $9.5 m.

  • What is Celldex Therapeutics revenue per employee?

    Latest Celldex Therapeutics revenue per employee is $71.7 k.

  • Who are Celldex Therapeutics competitors?

    Competitors of Celldex Therapeutics include Athersys, Reata Pharmaceuticals and Ironwood Pharmaceuticals.

  • Where is Celldex Therapeutics headquarters?

    Celldex Therapeutics headquarters is located at 53 I-78 Frontage Rd #220, Hampton.

  • Where are Celldex Therapeutics offices?

    Celldex Therapeutics has offices in Hampton, Branford, Fall River and Needham.

  • How many offices does Celldex Therapeutics have?

    Celldex Therapeutics has 4 offices.